Key Highlights

  • Q3 2026 net revenues of $84.7 million grew 71% year-over-year and 14% sequentially from Q2 2026
  • Positive Operating Cash Flow generated for the second consecutive quarter
  • Over 2 million total VOQUEZNA prescriptions filled since launch through October 16, 2026
  • Company reaffirmed full-year 2026 financial guidance; Phase 3 NERD trial initiated in September 2026

VOQUEZNA Revenue Accelerates

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on treatments for gastrointestinal diseases, reported net revenues of $84.7 million for the third quarter ended September 30, 2026. This represents a 71% increase from $49.5 million in Q3 2025 and a 14% sequential increase from Q2 2026, driven by continued execution of its commercial strategy for VOQUEZNA, its first-in-class potassium-competitive acid blocker approved for the treatment of GERD.

Approximately 380,000 total VOQUEZNA prescriptions were filled during Q3 2026, including approximately 248,000 covered prescriptions and 132,000 cash-pay prescriptions. Covered prescriptions accounted for 65% of the total quarterly Volume and grew approximately 19% sequentially from Q2 2026. Cash-pay prescriptions increased approximately 6% sequentially. Over 2 million total VOQUEZNA prescriptions have been filled since launch through October 16, 2026, with the second million reached less than a year after the first million.

Improving Financial Foundation

Phathom achieved positive operating cash flow for the second consecutive quarter, marking a meaningful step in its financial transformation. Research and Development expenses for Q3 2026 were $8.7 million, an increase of $1.7 million from Q3 2025, driven by higher clinical development and regulatory costs. Selling, general and administrative expenses were $57.7 million, an increase of $6.1 million year-over-year, primarily from higher promotional and personnel-related expenses.

CFO Sanjeev Narula noted that the company has established a financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in its commercial and clinical development priorities. Management expressed confidence in meeting the company's financial obligations and delivering on full-year 2026 guidance.

Access Initiatives and Physician Adoption

Phathom implemented several initiatives during the quarter to improve VOQUEZNA access, including an "Access First" field messaging approach and the introduction of a new copay offering through pharmacy partner BlinkRx at the end of Q3 2026. Under the BlinkRx program, eligible commercially insured patients may pay as little as $0 for VOQUEZNA, which management expects to support further prescription volume growth.

The company is continuing to grow VOQUEZNA prescribing depth among gastrointestinal specialists and has implemented physician outreach programs designed to expand usage in its core GERD indication. New data presented at the American College of Gastroenterology's 2026 Annual Scientific Meeting indicated that VOQUEZNA may be cost-effective compared with proton pump inhibitors, a positive development for market access discussions.

Pipeline Progress and Regulatory Exclusivity

In September 2026, Phathom initiated pHalcon-NERD-302, a registrational Phase 3 study of VOQUEZNA for as-needed use in Non-Erosive Gastroesophageal Reflux Disease. The first subject has been dosed and enrollment is ongoing across U.S. sites, with topline results expected in Q1 2028. If successful, the trial could support a label expansion allowing patients to take VOQUEZNA on an as-needed basis, potentially broadening the addressable market.

On the regulatory exclusivity front, Phathom is vigorously defending its statutory exclusivities for VOQUEZNA. The FDA granted Phathom 10 years of NCE exclusivity through May 3, 2032, as reflected in the Orange Book. In October 2026, the U.S. District Court for the District of Columbia granted Phathom's motion to intervene in litigation filed by BDR Pharmaceuticals against the FDA regarding VOQUEZNA's exclusivity.

Phathom Pharmaceuticals delivered a quarter marked by continued commercial momentum for VOQUEZNA, with revenue growth accelerating and the company generating positive cash flow from operations for the second consecutive period. With over 2 million prescriptions filled and a Phase 3 NERD trial underway, the company is working to extend VOQUEZNA's market reach beyond its current erosive GERD indication.

What drove Phathom's 71% revenue growth in Q3 2026?

Revenue growth was driven by continued prescriber adoption and expansion of VOQUEZNA, Phathom's first-in-class potassium-competitive acid blocker approved for GERD. Approximately 380,000 total prescriptions were filled in the quarter.

How many VOQUEZNA prescriptions have been filled in total?

Over 2 million total VOQUEZNA prescriptions were filled since launch through October 16, 2026. The second million prescriptions were reached in less than a year after the first million milestone.

What is Phathom's Phase 3 NERD trial?

Phathom initiated pHalcon-NERD-302 in September 2026, a registrational Phase 3 study evaluating VOQUEZNA for as-needed use in Non-Erosive Gastroesophageal Reflux Disease. Topline results are expected in Q1 2028.

Did Phathom Pharmaceuticals maintain its full-year 2026 guidance?

Yes, Phathom reaffirmed its full-year 2026 financial guidance and expressed confidence in meeting its financial obligations based on continued revenue growth and disciplined expense management.